LumiraDx was founded in 2014 by a group of entrepreneurs – Ron Zwanziger, our chairman and CEO; Dave Scott Ph.D., our chief technology officer, and Jerry McAleer, Ph.D., our chief scientist, who have a successful track record in building and scaling diagnostics and health IT businesses over three decades. (LumiraDx was incorporated in 2016 in the Cayman Islands.) We are a next-generation point of care (POC) diagnostic company addressing the current limitations of legacy POC systems by bringing lab-comparable performance to the POC in minutes on a single instrument with a low cost of ownership. 

In response to the COVID-19 pandemic, we developed our SARS-CoV-2 antigen and SARS-CoV-2 antibody tests for use in community-based healthcare settings. We have commenced commercial sales of our SARS-CoV-2 antigen test in Europe and the United States to customers, including the U.K. National Health Service (NHS) and CVS Pharmacy, Inc. (CVS), and we have commenced shipment of instruments to Africa as part of our collaboration with the Bill & Melinda Gates Foundation.

(Note: LumiraDX withdrew its IPO on April 7, 2021, in favor of going public through a merger with a SPAC called CA Healthcare Acquisition (CAHC). LumiraDX had filed its F-1 registration statement, or prospectus, on Jan. 15, 2021, according to SEC records.)